Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-200c-3p ACE2 2.07 0 -2.45 0 miRNATAP -0.32 2.0E-5 NA
2 hsa-miR-200c-3p ACTC1 2.07 0 -1.25 0 MirTarget -0.45 0 NA
3 hsa-miR-200c-3p ADAMTS3 2.07 0 -1.85 0 miRNATAP -0.38 0 NA
4 hsa-miR-200c-3p ARHGAP20 2.07 0 -3.51 0 MirTarget; miRNATAP -0.69 0 NA
5 hsa-miR-200c-3p ARHGAP28 2.07 0 -1.18 0 MirTarget -0.43 0 NA
6 hsa-miR-200c-3p ARHGAP6 2.07 0 -1.65 0 MirTarget -0.46 0 NA
7 hsa-miR-200c-3p BACH2 2.07 0 -1.74 0 mirMAP -0.34 0 NA
8 hsa-miR-200c-3p BNC2 2.07 0 -0.78 0 MirTarget -0.46 0 NA
9 hsa-miR-200c-3p C17orf51 2.07 0 -1.38 0 mirMAP -0.36 0 NA
10 hsa-miR-200c-3p CALCR 2.07 0 -2.1 0 MirTarget -0.36 0 NA
11 hsa-miR-200c-3p CCDC82 2.07 0 -1.57 0 MirTarget -0.3 0 NA
12 hsa-miR-200c-3p CELF2 2.07 0 -2.12 0 mirMAP; miRNATAP -0.45 0 NA
13 hsa-miR-200c-3p CFL2 2.07 0 -1.91 0 MirTarget; miRNATAP -0.38 0 23497265 We characterized one of the target genes of miR-200c CFL2 and demonstrated that CFL2 is overexpressed in aggressive breast cancer cell lines and can be significantly down-regulated by exogenous miR-200c
14 hsa-miR-200c-3p CHRDL1 2.07 0 -5.4 0 MirTarget -0.92 0 NA
15 hsa-miR-200c-3p CNTFR 2.07 0 -4.18 0 miRNATAP -0.65 0 NA
16 hsa-miR-200c-3p CNTN1 2.07 0 -2.3 0 MirTarget; miRNATAP -0.49 0 NA
17 hsa-miR-200c-3p CNTN4 2.07 0 -1.68 0 miRNATAP -0.35 0 NA
18 hsa-miR-200c-3p CREB5 2.07 0 -2.35 0 miRNATAP -0.48 0 NA
19 hsa-miR-200c-3p CRHBP 2.07 0 -3.67 0 MirTarget -0.75 0 NA
20 hsa-miR-200c-3p CRYBG3 2.07 0 -2.3 0 miRNATAP -0.49 0 NA
21 hsa-miR-200c-3p CSRNP3 2.07 0 -3.02 0 MirTarget; miRNATAP -0.42 0 NA
22 hsa-miR-200c-3p DDIT4L 2.07 0 -1.72 0 MirTarget -0.4 0 NA
23 hsa-miR-200c-3p DIXDC1 2.07 0 -1.64 0 MirTarget -0.32 0 NA
24 hsa-miR-200c-3p DLC1 2.07 0 -1.85 0 miRNATAP -0.45 0 NA
25 hsa-miR-200c-3p DMD 2.07 0 -3.78 0 miRNATAP -0.59 0 NA
26 hsa-miR-200c-3p DMRT2 2.07 0 -3.09 0 miRNATAP -0.57 0 NA
27 hsa-miR-200c-3p DST 2.07 0 -2.66 0 mirMAP -0.37 0 NA
28 hsa-miR-200c-3p DUSP1 2.07 0 -2.1 0 MirTarget; miRNATAP -0.46 0 NA
29 hsa-miR-200c-3p DYNC1I1 2.07 0 -1.58 0 MirTarget -0.31 0 NA
30 hsa-miR-200c-3p FAT3 2.07 0 -1.4 0 MirTarget; miRNATAP -0.55 0 NA
31 hsa-miR-200c-3p FBLN5 2.07 0 -2.09 0 miRNAWalker2 validate; miRTarBase -0.43 0 NA
32 hsa-miR-200c-3p FGF2 2.07 0 -3.62 0 mirMAP -0.62 0 NA
33 hsa-miR-200c-3p FHL1 2.07 0 -4.4 0 MirTarget -0.95 0 NA
34 hsa-miR-200c-3p FIGN 2.07 0 -2.44 0 MirTarget -0.37 0 NA
35 hsa-miR-200c-3p FLI1 2.07 0 -1.26 0 MirTarget; miRNATAP -0.34 0 NA
36 hsa-miR-200c-3p FSTL1 2.07 0 -1.28 0 MirTarget -0.45 0 NA
37 hsa-miR-200c-3p FYN 2.07 0 -0.97 0 miRNATAP -0.31 0 NA
38 hsa-miR-200c-3p FZD4 2.07 0 -2.46 0 mirMAP -0.54 0 NA
39 hsa-miR-200c-3p GABRB3 2.07 0 -1.55 0 mirMAP -0.37 0 NA
40 hsa-miR-200c-3p GEM 2.07 0 -1.31 0 MirTarget; miRNATAP -0.34 0 NA
41 hsa-miR-200c-3p GPM6A 2.07 0 -3.1 0 miRNATAP -0.52 0 NA
42 hsa-miR-200c-3p GPR12 2.07 0 -3.8 0 mirMAP -0.36 1.0E-5 NA
43 hsa-miR-200c-3p GPR146 2.07 0 -2.69 0 miRNATAP -0.49 0 NA
44 hsa-miR-200c-3p HLF 2.07 0 -3.73 0 MirTarget; miRNATAP -0.55 0 NA
45 hsa-miR-200c-3p HTR2A 2.07 0 -3.25 0 MirTarget -0.55 0 NA
46 hsa-miR-200c-3p IGSF10 2.07 0 -3.95 0 MirTarget -0.72 0 NA
47 hsa-miR-200c-3p IL6ST 2.07 0 -1.53 0 mirMAP -0.32 0 NA
48 hsa-miR-200c-3p ITGA1 2.07 0 -1.3 0 MirTarget -0.35 0 NA
49 hsa-miR-200c-3p KCNJ2 2.07 0 -1.76 0 miRNATAP -0.31 0 NA
50 hsa-miR-200c-3p KIAA1462 2.07 0 -0.89 0 MirTarget -0.36 0 NA
51 hsa-miR-200c-3p KLF4 2.07 0 -2.57 0 MirTarget; miRNATAP -0.48 0 NA
52 hsa-miR-200c-3p KLF9 2.07 0 -1.74 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.37 0 NA
53 hsa-miR-200c-3p KLHL29 2.07 0 -2.95 0 MirTarget -0.49 0 NA
54 hsa-miR-200c-3p KLHL3 2.07 0 -1.43 0 miRNATAP -0.32 0 NA
55 hsa-miR-200c-3p KLHL31 2.07 0 -3.32 0 MirTarget -0.5 0 NA
56 hsa-miR-200c-3p LAMC1 2.07 0 -1.23 0 MirTarget; miRNATAP -0.33 0 NA
57 hsa-miR-200c-3p LHFP 2.07 0 -2.16 0 MirTarget; miRNATAP -0.51 0 NA
58 hsa-miR-200c-3p LIX1L 2.07 0 -1.12 0 MirTarget -0.32 0 NA
59 hsa-miR-200c-3p LPAR1 2.07 0 -1.21 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.35 0 NA
60 hsa-miR-200c-3p LRP1B 2.07 0 -2.79 0 MirTarget; miRNATAP -0.48 0 NA
61 hsa-miR-200c-3p LRP4 2.07 0 -1.81 0 MirTarget; miRNATAP -0.35 0 NA
62 hsa-miR-200c-3p MAF 2.07 0 -1.16 0 miRNATAP -0.32 0 NA
63 hsa-miR-200c-3p MBNL3 2.07 0 -1.93 0 MirTarget; mirMAP -0.35 0 NA
64 hsa-miR-200c-3p MFAP5 2.07 0 -1.74 0 miRNATAP -0.5 0 NA
65 hsa-miR-200c-3p MGAT3 2.07 0 -1.92 0 miRNATAP -0.35 0 NA
66 hsa-miR-200c-3p MITF 2.07 0 -1.35 0 miRNATAP -0.38 0 NA
67 hsa-miR-200c-3p MMD 2.07 0 -2.3 0 miRNATAP -0.5 0 NA
68 hsa-miR-200c-3p MRVI1 2.07 0 -1.29 0 MirTarget -0.35 0 NA
69 hsa-miR-200c-3p MSRB3 2.07 0 -2.05 0 mirMAP -0.51 0 NA
70 hsa-miR-200c-3p NCAM1 2.07 0 -2.68 0 miRTarBase -0.54 0 NA
71 hsa-miR-200c-3p NDN 2.07 0 -1.9 0 MirTarget; miRNATAP -0.54 0 NA
72 hsa-miR-200c-3p NEGR1 2.07 0 -1.48 0 miRNATAP -0.49 0 NA
73 hsa-miR-200c-3p NLGN4X 2.07 0 -2.19 0 miRNATAP -0.43 0 NA
74 hsa-miR-200c-3p NOG 2.07 0 -0.84 4.0E-5 MirTarget; miRNATAP -0.35 0 NA
75 hsa-miR-200c-3p NOVA1 2.07 0 -2.65 0 MirTarget; miRNATAP -0.44 0 NA
76 hsa-miR-200c-3p NR3C1 2.07 0 -1.9 0 miRNATAP -0.37 0 NA
77 hsa-miR-200c-3p NR5A2 2.07 0 -1.74 0 miRNATAP -0.42 0 NA
78 hsa-miR-200c-3p NRG1 2.07 0 -2.73 0 miRNATAP -0.32 0 NA
79 hsa-miR-200c-3p NTF3 2.07 0 -2.35 0 miRNAWalker2 validate; miRNATAP -0.41 0 NA
80 hsa-miR-200c-3p NTRK2 2.07 0 -4.04 0 miRNAWalker2 validate; miRTarBase -0.54 0 23209748; 23074172 miR 200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression;miR-200c also targets TrkB a mediator of resistance to anoikis
81 hsa-miR-200c-3p OSR1 2.07 0 -3.17 0 miRNATAP -0.44 0 NA
82 hsa-miR-200c-3p PALM2-AKAP2 2.07 0 -2.18 0 miRNATAP -0.45 0 NA
83 hsa-miR-200c-3p PARD3B 2.07 0 -1.79 0 MirTarget; miRNATAP -0.35 0 NA
84 hsa-miR-200c-3p PCDH19 2.07 0 -2.02 0 miRNATAP -0.47 0 NA
85 hsa-miR-200c-3p PCSK2 2.07 0 -1.42 3.0E-5 miRNATAP -0.39 0 NA
86 hsa-miR-200c-3p PDE7B 2.07 0 -1.82 0 miRNATAP -0.43 0 NA
87 hsa-miR-200c-3p PHLDB1 2.07 0 -1.05 0 MirTarget; miRNATAP -0.32 0 NA
88 hsa-miR-200c-3p PKIA 2.07 0 -1.54 0 MirTarget; miRNATAP -0.36 0 NA
89 hsa-miR-200c-3p PLXNA4 2.07 0 -3.24 0 miRNATAP -0.7 0 NA
90 hsa-miR-200c-3p PPARGC1A 2.07 0 -2.62 0 mirMAP -0.43 0 NA
91 hsa-miR-200c-3p PRDM16 2.07 0 -2.1 0 MirTarget; miRNATAP -0.47 0 NA
92 hsa-miR-200c-3p PRKCA 2.07 0 -1.71 0 miRNATAP -0.38 0 NA
93 hsa-miR-200c-3p PRKG1 2.07 0 -1.38 0 miRNATAP -0.39 0 NA
94 hsa-miR-200c-3p PTPN21 2.07 0 -1.65 0 miRNATAP -0.37 0 NA
95 hsa-miR-200c-3p PTPRD 2.07 0 0.15 0.42781 miRNAWalker2 validate -0.34 0 NA
96 hsa-miR-200c-3p PTPRZ1 2.07 0 -4.21 0 MirTarget; miRNATAP -0.51 0 NA
97 hsa-miR-200c-3p PYGO1 2.07 0 -1.89 0 mirMAP -0.38 0 NA
98 hsa-miR-200c-3p RECK 2.07 0 -1.98 0 miRNATAP -0.48 0 27574450; 24647918 MiR 200c promotes bladder cancer cell migration and invasion by directly targeting RECK; The luciferase reporter assay showed that RECK was a direct target of miR-200c;Finally we demonstrated that expression of miR-200c in H460 cells suppressed cell growth by targeting RECK followed by activation of the JNK signaling pathway and ER stress; Collectively these data show that miR-200c expression sensitizes H460 cells to RESV and this is likely due to RECK expression
99 hsa-miR-200c-3p RELN 2.07 0 -4.67 0 MirTarget -0.83 0 NA
100 hsa-miR-200c-3p RFTN2 2.07 0 -1.5 0 MirTarget -0.45 0 NA
101 hsa-miR-200c-3p RGL1 2.07 0 -1.67 0 MirTarget; miRNATAP -0.37 0 NA
102 hsa-miR-200c-3p SCN2A 2.07 0 -3.32 0 MirTarget; miRNATAP -0.42 0 NA
103 hsa-miR-200c-3p SCN3A 2.07 0 -4.06 0 mirMAP -0.68 0 NA
104 hsa-miR-200c-3p SCN5A 2.07 0 -2.93 0 miRNATAP -0.4 0 NA
105 hsa-miR-200c-3p SEMA6D 2.07 0 -2.5 0 miRNATAP -0.47 0 NA
106 hsa-miR-200c-3p SGCD 2.07 0 -1.03 0 mirMAP -0.43 0 NA
107 hsa-miR-200c-3p SHE 2.07 0 -2.33 0 mirMAP -0.5 0 NA
108 hsa-miR-200c-3p SHROOM4 2.07 0 -1.47 0 mirMAP -0.35 0 NA
109 hsa-miR-200c-3p SLC14A1 2.07 0 -1.83 0 miRNATAP -0.35 0 NA
110 hsa-miR-200c-3p SLC16A12 2.07 0 -3.4 0 mirMAP; miRNATAP -0.56 0 NA
111 hsa-miR-200c-3p SLC38A4 2.07 0 -1.23 0 miRNATAP -0.44 0 NA
112 hsa-miR-200c-3p SLC4A4 2.07 0 -3.22 0 mirMAP -0.63 0 NA
113 hsa-miR-200c-3p SOX6 2.07 0 -2.37 0 mirMAP; miRNATAP -0.41 0 NA
114 hsa-miR-200c-3p STARD8 2.07 0 -1.15 0 mirMAP -0.34 0 NA
115 hsa-miR-200c-3p SV2B 2.07 0 -2.65 0 mirMAP -0.49 0 NA
116 hsa-miR-200c-3p TBX18 2.07 0 -1.63 0 MirTarget -0.46 0 NA
117 hsa-miR-200c-3p TCF4 2.07 0 -1.1 0 mirMAP; miRNATAP -0.37 0 NA
118 hsa-miR-200c-3p TEAD1 2.07 0 -1.4 0 miRNATAP -0.3 0 NA
119 hsa-miR-200c-3p TFPI 2.07 0 -2.25 0 MirTarget -0.51 0 NA
120 hsa-miR-200c-3p TIMP2 2.07 0 -0.79 0 miRTarBase -0.35 0 NA
121 hsa-miR-200c-3p TLN2 2.07 0 -1.84 0 miRNATAP -0.4 0 NA
122 hsa-miR-200c-3p TRHDE 2.07 0 -4.57 0 MirTarget -0.97 0 NA
123 hsa-miR-200c-3p VAT1L 2.07 0 -1.43 0 MirTarget; miRNATAP -0.4 0 NA
124 hsa-miR-200c-3p VGLL3 2.07 0 -2.1 0 mirMAP -0.49 0 NA
125 hsa-miR-200c-3p VLDLR 2.07 0 -1.77 0 miRNATAP -0.36 0 NA
126 hsa-miR-200c-3p WASF3 2.07 0 -2.53 0 miRNATAP -0.46 0 NA
127 hsa-miR-200c-3p XG 2.07 0 -1.55 0 MirTarget -0.42 0 NA
128 hsa-miR-200c-3p ZC3H12C 2.07 0 -1.87 0 miRNATAP -0.31 0 NA
129 hsa-miR-200c-3p ZCCHC24 2.07 0 -1.58 0 MirTarget; miRNATAP -0.47 0 NA
130 hsa-miR-200c-3p ZEB1 2.07 0 -1.2 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.42 0 24710933; 24615544; 21682933; 27717206; 23626803; 27666124; 23754305; 24424572; 24186205; 22407310 miR-200c has been shown to regulate the epithelial-mesenchymal transition EMT by inhibiting ZEB1 and ZEB2 expression in breast cancer cells; This study further examined the role of miR-200c in the invasion and metastasis of breast cancer that goes beyond the regulation on ZEB1 and ZEB2 expression;MiR 200c suppresses TGF β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer; MiR-200c which was the most significantly downregulated miRNA in trastuzumab-resistant cells restored trastuzumab sensitivity and suppressed invasion of breast cancer cells by concurrently targeting ZNF217 a transcriptional activator of TGF-β and ZEB1 a known mediator of TGF-β signaling; Given the reported backward inhibition of miR-200c by ZEB1 ZNF217 also exerts a feedback suppression of miR-200c via TGF-β/ZEB1 signaling; Restoration of miR-200c silencing of ZEB1 or ZNF217 or blockade of TGF-β signaling increased trastuzumab sensitivity and suppressed invasiveness of breast cancer cells;Of this family miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2 mediators of epithelial- mesenchymal transition;Epigenetic Silencing of miR 200c in Breast Cancer Is Associated with Aggressiveness and Is Modulated by ZEB1;Concomitant with the increase in miR-200b and miR-200c ZEB1 expression was decreased and cells appeared more epithelial in morphology and were sensitized to TAM and fulvestrant inhibition;miR 200c regulates crizotinib resistant ALK positive lung cancer cells by reversing epithelial mesenchymal transition via targeting ZEB1;Overexpression of miR-200c in SN12-PM6 and 786-0 cells was concurrent with downregulation of ZEB1 and upregulation of E-cadherin mRNA and protein; Thus our study demonstrated that miR-200c decreases the metastatic ability of renal carcinoma cells by upregulating E-cadherin through ZEB1 and that modulating the expression of miR-200c could influence Akt protein levels;Accordingly the enforced expression of miR-200c and mir-141 resulted in a significant upregulation in E-cadherin expression contrary to the significant downregulation in ZEB1 expression in 3 cell lines UTSCC-24A UTSCC-24B and UTSCC-6A cells;Furthermore miR-200c was found to be important in modulating ZEB1 upregulation by ERG;miR 200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1; Among those dysregulated microRNAs miR-200c was speculated to inhibit metastasis by targeting ZEB1; Overexpression of miR-200c was concurrent with downregulation of ZEB1 mRNA and protein; Taken together our study demonstrated that miR-200c inhibits metastatic ability by targeting ZEB1 in colon cancer cells SW480/620 and suggested that modulation of miR-200c could serve as therapeutic tool for inhibiting metastasis in colorectal cancer
131 hsa-miR-200c-3p ZEB2 2.07 0 -1.6 0 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.47 0 24710933; 21682933; 26935975; 25052237; 18925646; 24885194 miR-200c has been shown to regulate the epithelial-mesenchymal transition EMT by inhibiting ZEB1 and ZEB2 expression in breast cancer cells; This study further examined the role of miR-200c in the invasion and metastasis of breast cancer that goes beyond the regulation on ZEB1 and ZEB2 expression;Of this family miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2 mediators of epithelial- mesenchymal transition;MicroRNA 200c inhibits the metastasis of non small cell lung cancer cells by targeting ZEB2 an epithelial mesenchymal transition regulator;miR 200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E box binding homeobox 2 ZEB2 expression; Luciferase reporter assay confirmed the target of miR-200c as ZEB2; Furthermore miR-200c expression inhibited ovarian cancer cell ES-2 migration and invasion capacity by suppression of ZEB2 expression p < 0.01; Thus targeting of miR-200c or ZEB2 may serve as a potential therapeutic strategy for control of ovarian cancer;We established by quantitative RT-PCR that in CCCs in which miR-141 and miR-200c were down-regulated ZFHX1B a transcriptional repressor for CDH1/E-cadherin tended to be up-regulated; On the basis of these findings we suggest that down-regulation of miR-141 and miR-200c in CCCs might be involved in suppression of CDH1/E-cadherin transcription via up-regulation of ZFHX1B;Two gastric cancer cell lines were treated with IGF-I to induce EMT and levels of transcription factor ZEB2 and microRNA-200c miR-200c were measured; Furthermore both Akt/ERK inhibitors and knockdown of Akt/ERK gene reversed IGF-I-induced ZEB2 up-regulation and EMT through up-regulation of miR-200c suggesting the involvement of an Akt/ERK-miR-200c-ZEB2 axis in IGF-I-induced EMT
132 hsa-miR-200c-3p ZFHX4 2.07 0 -1.53 0 miRNATAP -0.51 0 NA
133 hsa-miR-200c-3p ZFPM2 2.07 0 -1.48 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.49 0 NA
134 hsa-miR-200c-3p ZNF423 2.07 0 -1.54 0 MirTarget -0.47 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF NEURON DIFFERENTIATION 24 554 3.014e-13 1.402e-09
2 NEUROGENESIS 36 1402 1.221e-12 2.841e-09
3 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 26 750 4.441e-12 5.166e-09
4 CENTRAL NERVOUS SYSTEM DEVELOPMENT 28 872 3.654e-12 5.166e-09
5 REGULATION OF CELL DIFFERENTIATION 36 1492 7.444e-12 6.928e-09
6 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 38 1672 9.939e-12 7.708e-09
7 REGULATION OF CELL DEVELOPMENT 26 836 4.919e-11 3.27e-08
8 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 30 1142 8.041e-11 4.677e-08
9 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 19 437 1.064e-10 5.502e-08
10 CELL DEVELOPMENT 33 1426 2.071e-10 9.638e-08
11 POSITIVE REGULATION OF NEURON DIFFERENTIATION 16 306 2.444e-10 1.034e-07
12 HEAD DEVELOPMENT 22 709 1.915e-09 7.427e-07
13 POSITIVE REGULATION OF CELL DEVELOPMENT 18 472 2.759e-09 9.875e-07
14 POSITIVE REGULATION OF CELL DIFFERENTIATION 23 823 5.738e-09 1.907e-06
15 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 30 1395 9.071e-09 2.814e-06
16 REGULATION OF NEURON PROJECTION DEVELOPMENT 16 408 1.52e-08 4.421e-06
17 FOREBRAIN DEVELOPMENT 15 357 1.776e-08 4.86e-06
18 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 12 232 5.413e-08 1.399e-05
19 NEURON DIFFERENTIATION 22 874 8.174e-08 2.002e-05
20 CELLULAR COMPONENT MORPHOGENESIS 22 900 1.359e-07 3.012e-05
21 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 13 303 1.316e-07 3.012e-05
22 REGULATION OF CELL PROJECTION ORGANIZATION 17 558 2.033e-07 4.3e-05
23 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 23 1021 2.91e-07 5.888e-05
24 LOCOMOTION 24 1114 3.481e-07 6.749e-05
25 NEURON PROJECTION MORPHOGENESIS 14 402 5.377e-07 0.0001001
26 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 31 1784 6.081e-07 0.0001088
27 NEURON DEVELOPMENT 18 687 7.88e-07 0.0001309
28 NEURON PROJECTION DEVELOPMENT 16 545 7.784e-07 0.0001309
29 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 25 1275 1.091e-06 0.0001751
30 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 22 1036 1.46e-06 0.0002147
31 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 22 1036 1.46e-06 0.0002147
32 POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 9 162 1.477e-06 0.0002147
33 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 30 1805 2.423e-06 0.0003417
34 REGULATION OF PHOSPHORUS METABOLIC PROCESS 28 1618 2.616e-06 0.0003581
35 OLIGODENDROCYTE DIFFERENTIATION 6 60 3.008e-06 0.0003998
36 POSITIVE REGULATION OF GENE EXPRESSION 29 1733 3.248e-06 0.0004051
37 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 21 1004 3.308e-06 0.0004051
38 TELENCEPHALON DEVELOPMENT 10 228 3.235e-06 0.0004051
39 HINDBRAIN DEVELOPMENT 8 137 3.984e-06 0.0004754
40 POSITIVE REGULATION OF DENDRITE DEVELOPMENT 6 64 4.406e-06 0.0005126
41 BIOLOGICAL ADHESION 21 1032 5.069e-06 0.0005753
42 REGULATION OF PHOSPHOLIPASE C ACTIVITY 5 39 6.006e-06 0.0006654
43 CIRCULATORY SYSTEM PROCESS 12 366 6.703e-06 0.0007153
44 REGULATION OF MUSCLE SYSTEM PROCESS 9 195 6.764e-06 0.0007153
45 REGULATION OF SYSTEM PROCESS 14 507 8.018e-06 0.000829
46 CELL PROJECTION ORGANIZATION 19 902 9.259e-06 0.0009366
47 BEHAVIOR 14 516 9.778e-06 0.0009681
48 REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 9 213 1.375e-05 0.001333
49 REGULATION OF DENDRITE DEVELOPMENT 7 120 1.642e-05 0.001559
50 MUSCLE ORGAN DEVELOPMENT 10 277 1.781e-05 0.001658
51 REGULATION OF CELL MORPHOGENESIS 14 552 2.074e-05 0.001892
52 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 21 1135 2.138e-05 0.001909
53 REGULATION OF PROTEIN MODIFICATION PROCESS 27 1710 2.174e-05 0.001909
54 CELL PART MORPHOGENESIS 15 633 2.289e-05 0.001972
55 GLIOGENESIS 8 175 2.391e-05 0.002023
56 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 9 229 2.441e-05 0.002028
57 POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY 5 53 2.777e-05 0.002267
58 ACTIVATION OF PHOSPHOLIPASE C ACTIVITY 4 27 3e-05 0.002407
59 GLIAL CELL DIFFERENTIATION 7 136 3.687e-05 0.002908
60 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 11 368 3.848e-05 0.002984
61 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 13 513 4.188e-05 0.003195
62 MESENCHYME DEVELOPMENT 8 190 4.301e-05 0.003228
63 SYSTEM PROCESS 27 1785 4.613e-05 0.003407
64 COGNITION 9 251 4.996e-05 0.003632
65 REGULATION OF CELL PROLIFERATION 24 1496 5.258e-05 0.003764
66 SYNAPSE ORGANIZATION 7 145 5.548e-05 0.003912
67 METENCEPHALON DEVELOPMENT 6 100 5.754e-05 0.003996
68 REGULATION OF CELLULAR COMPONENT MOVEMENT 16 771 5.959e-05 0.004077
69 REGULATION OF MUSCLE ADAPTATION 5 63 6.447e-05 0.004347
70 TISSUE DEVELOPMENT 24 1518 6.618e-05 0.004399
71 REGULATION OF HYDROLASE ACTIVITY 22 1327 6.984e-05 0.004451
72 TAXIS 12 464 6.895e-05 0.004451
73 REGULATION OF PHOSPHOLIPASE ACTIVITY 5 64 6.956e-05 0.004451
74 POSITIVE REGULATION OF LIPASE ACTIVITY 5 66 8.066e-05 0.005072
75 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 20 1152 8.317e-05 0.00516
76 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 10 337 9.291e-05 0.005628
77 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 16 801 9.314e-05 0.005628
78 NEURON MIGRATION 6 110 9.789e-05 0.005839
79 SYNAPSE ASSEMBLY 5 69 9.982e-05 0.005879
80 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 15 724 0.0001047 0.006088
81 REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 9 278 0.0001092 0.006274
82 SENSORY ORGAN DEVELOPMENT 12 493 0.0001221 0.00693
83 REGULATION OF N METHYL D ASPARTATE SELECTIVE GLUTAMATE RECEPTOR ACTIVITY 3 15 0.0001262 0.007072
84 MEMBRANE DEPOLARIZATION DURING ACTION POTENTIAL 4 39 0.0001321 0.007318
85 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 18 1008 0.0001375 0.007528
86 CELL MOTILITY 16 835 0.0001503 0.008039
87 LOCALIZATION OF CELL 16 835 0.0001503 0.008039
88 MUSCLE STRUCTURE DEVELOPMENT 11 432 0.0001599 0.008416
89 CELL SUBSTRATE JUNCTION ASSEMBLY 4 41 0.000161 0.008416
90 POSITIVE REGULATION OF CATALYTIC ACTIVITY 23 1518 0.0001806 0.009338
91 DENDRITE DEVELOPMENT 5 79 0.0001898 0.009703
NumGOOverlapSizeP ValueAdj. P Value
NumGOOverlapSizeP ValueAdj. P Value
1 CELL BODY 17 494 3.556e-08 2.077e-05
2 SOMATODENDRITIC COMPARTMENT 18 650 3.535e-07 0.0001032
3 NEURON PROJECTION 21 942 1.21e-06 0.0002355
4 DENDRITE 14 451 2.091e-06 0.0003052
5 NEURON PART 23 1265 1.087e-05 0.001104
6 INTRINSIC COMPONENT OF PLASMA MEMBRANE 27 1649 1.134e-05 0.001104
7 MEMBRANE REGION 21 1134 2.11e-05 0.00176
8 MEMBRANE MICRODOMAIN 10 288 2.487e-05 0.001815
9 ANCHORED COMPONENT OF MEMBRANE 7 152 7.476e-05 0.004851
10 VOLTAGE GATED SODIUM CHANNEL COMPLEX 3 14 0.0001014 0.005923
11 CELL PROJECTION 26 1786 0.000123 0.006528
12 CELL SURFACE 15 757 0.0001705 0.008297
13 SODIUM CHANNEL COMPLEX 3 17 0.0001867 0.008387
14 POSTSYNAPSE 10 378 0.0002359 0.009464
15 CELL JUNCTION 19 1151 0.0002431 0.009464

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04510_Focal_adhesion 6 200 0.002309 0.1861
2 hsa04512_ECM.receptor_interaction 4 85 0.002565 0.1861
3 hsa04540_Gap_junction 4 90 0.003155 0.1861
4 hsa04514_Cell_adhesion_molecules_.CAMs. 4 136 0.01331 0.589
5 hsa04666_Fc_gamma_R.mediated_phagocytosis 3 95 0.02604 0.7765
6 hsa04916_Melanogenesis 3 101 0.03046 0.7765
7 hsa04010_MAPK_signaling_pathway 5 268 0.0345 0.7765
8 hsa04962_Vasopressin.regulated_water_reabsorption 2 44 0.03509 0.7765
9 hsa04270_Vascular_smooth_muscle_contraction 3 116 0.04314 0.8483
10 hsa04380_Osteoclast_differentiation 3 128 0.05489 0.9168
11 hsa04360_Axon_guidance 3 130 0.05698 0.9168
12 hsa04730_Long.term_depression 2 70 0.08015 1
13 hsa04520_Adherens_junction 2 73 0.08611 1
14 hsa04971_Gastric_acid_secretion 2 74 0.08813 1
15 hsa04664_Fc_epsilon_RI_signaling_pathway 2 79 0.09842 1
16 hsa04012_ErbB_signaling_pathway 2 87 0.1155 1
17 hsa04970_Salivary_secretion 2 89 0.1199 1
18 hsa04972_Pancreatic_secretion 2 101 0.1471 1
19 hsa04810_Regulation_of_actin_cytoskeleton 3 214 0.1735 1
20 hsa04722_Neurotrophin_signaling_pathway 2 127 0.2092 1
21 hsa04650_Natural_killer_cell_mediated_cytotoxicity 2 136 0.2314 1
22 hsa04310_Wnt_signaling_pathway 2 151 0.2686 1
23 hsa04630_Jak.STAT_signaling_pathway 2 155 0.2785 1
24 hsa04020_Calcium_signaling_pathway 2 177 0.3328 1

Quest ID: ce00d1f510d04f139508214ba10e1840